Naftidrofuryl

Naftidrofuryl
Clinical data
Trade names Praxilene
AHFS/Drugs.com International Drug Names
Routes of
administration		 Oral
ATC code C04AX21 (WHO)
Legal status
Legal status
  • UK: POM (Prescription only)
Pharmacokinetic data
Metabolism Hepatic
Biological half-life 1 - 3.5 hours
Identifiers
CAS Number 31329-57-4 YesY
PubChem (CID) 4417
ChemSpider 4264 YesY
UNII 42H8PQ0NMJ YesY
ChEMBL CHEMBL1620794
ECHA InfoCard 100.045.960
Chemical and physical data
Formula C24H33NO3
Molar mass 383.524 g/mol
3D model (Jmol) Interactive image
  (verify)

Naftidrofuryl (INN), also known as nafronyl or as the oxalate salt naftidrofuryl oxalate or nafronyl oxalate, is a vasodilator used in the management of peripheral and cerebral vascular disorders. It is also claimed to enhance cellular oxidative capacity. The drug act as a selective antagonist of 5-HT2 receptors (with action as an inverse agonist of the 5-HT2A receptor specifically characterized).[1][2][3] Naftidrofuryl is also licensed for the treatment of intermittent claudication due to peripheral arterial disease.

Naftidrofuryl is marketed under a variety of trade names, including Artocoron, Azunaftil, Di-Actane, Dusodril, Enelbin, Frilix, Gevatran, Iridus, Iridux, Luctor, Nafti, Naftoling, Naftodril, Nafoxal, Praxilene, Sodipryl retard, and Vascuprax.

Historically, it has been used to treat sudden idiopathic hearing loss and acute tinnitus.[4]

Naftidrofuryl may be effective for relieving the pain of muscle cramps.[5]

Adverse Effects

Naftidrofuryl has been associated with nausea, abdominal pain and rash. Rarely, hepatitis and liver failure have been reported.[6]

Synthesis

Prepn: Szarvasi, Bayssat, FR 1363948  corresp to U.S. Patent 3,334,096 (1964, 1967 both to LIPHA);[7] eidem[8]

See also

References

  1. ↑ Peter Lanzer; Eric J. Topol (20 December 2013). Pan Vascular Medicine: Integrated Clinical Management. Springer. pp. 1394–. ISBN 978-3-642-56225-9.
  2. ↑ I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 147–. ISBN 978-94-011-4439-1.
  3. ↑ Aly, Saida Abdel Regal; Hossain, Murad; Bhuiyan, Mohiuddin Ahmed; Nakamura, Takashi; Nagatomo, Takafumi (2009). "Assessment of Binding Affinity to 5-Hydroxytryptamine 2A (5-HT2A) Receptor and Inverse Agonist Activity of Naftidrofuryl: Comparison With Those of Sarpogrelate". Journal of Pharmacological Sciences. 110 (4): 445–450. doi:10.1254/jphs.09124FP. ISSN 1347-8613.
  4. ↑ http://www.der-arzneimittelbrief.de/Jahrgang2004/Ausgabe12Seite89.htm
  5. ↑ Katzberg HD, Khan AH, So YT (February 2010). "Assessment: Symptomatic treatment for muscle cramps (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology". Neurology. 74 (8): 691–6. doi:10.1212/WNL.0b013e3181d0ccca. PMID 20177124.
  6. ↑ Brayfield, A, ed. (14 January 2014). "Naftidrofuryl Oxalate". Martindale: The Complete Drug Reference. Pharmaceutical Press. Retrieved 6 August 2014.
  7. ↑ Szarvasi et al., Compt. Rend. 260, 3095 (1965).
  8. ↑ Bull. Soc. Chim. Fr. 1966, 1838.



This article is issued from Wikipedia - version of the 10/16/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.